Source: Eur Respir Mon; 2003: 27: 57–83
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Delcroix, W. Budts, P.A. Corris, W. Daenen, M. Gewillig, R. Naeije, H. Olschewski, J. Pepke-Zaba, W. Seeger, J-L. Vachiéry, D. Van Raemdonck, C.D. Vizza, and the other participants of the working group “Pulmonary arterial hypertension”. Pulmonary arterial hypertension: current therapies. Eur Respir Mon; 2003: 27: 57–83

Member's Comments

No comment yet.

Related content which might interest you: Medical treatment of pulmonary arterial hypertension Source: ISSN=1025-448x, ISBN=1-904097-29-4, page=31 Year: 2003 Effect of atrial septostomy on the survival of patients with severe pulmonary arterial hypertension Source: Eur Respir J 2011; 38: 1343-1348 Year: 2011 Chronic thromboembolic pulmonary hypertension: role of medical therapy Source: Eur Respir J 2013; 41: 985-990 Year: 2013 Current medical therapies in pulmonary arterial hypertension Source: Eur Respir Mon 2012; 57: 26-41 Year: 2012 Vascular and right ventricular remodelling in chronic thromboembolic pulmonary hypertension Source: Eur Respir J 2013; 41: 224-232 Year: 2013 Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension Source: Eur Respir J 2004; 23: 595-600 Year: 2004 Prostacyclin therapies for the treatment of pulmonary arterial hypertension Source: Eur Respir J 2008; 31: 891-901 Year: 2008 Goal-oriented treatment and combination therapy for pulmonary arterial hypertension Source: Eur Respir J 2005; 26: 858-863 Year: 2005 Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil Source: Eur Respir J 2006; 28: 1195-1203 Year: 2006 The influence of fractional pulse pressure on the outcome of pulmonary thromboendarterectomy Source: Eur Respir J 2001; 17: 653-659 Year: 2001 Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH) Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children Source: Eur Respir J 2011; 37: 70-77 Year: 2011 Long-term outcome in pulmonary arterial hypertension: a plea for earlier parenteral prostacyclin therapy Source: Eur Respir Rev 2009; 18: 253-259 Year: 2009 Long-term outcome with intravenous iloprost in pulmonary arterial hypertension Source: Eur Respir J 2009; 34: 132-137 Year: 2009 Chronic thromboembolic pulmonary hypertension: animal models Source: Eur Respir J 2013; 41: 1200-1206 Year: 2013 Hemodynamic effects of sildenafil in pulmonary arterial hypertension (PAH) patients Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension Year: 2005 Surgical and post-operative treatment of chronic thromboembolic pulmonary hypertension Source: Eur Respir Rev 2009; 19: 64-67 Year: 2010 How prostacyclin therapy improves right ventricular function in pulmonary arterial hypertension Source: Eur Respir J, 50 (2) 1700764; 10.1183/13993003.00764-2017 Year: 2017